Mirogabalin hits goals in late-stage pain syndromes trials

Shares of Japanese pharma major Daiichi Sankyo (TYO: 4568) were up 1.2% at 2,647 yen early afternoon today, after the company announced top-line results from NEUCOURSE, a Phase III clinical trial in patients with post-herpetic neuralgia, and the ALDAY Phase III clinical trials in patients with fibromyalgia.

The NEUCOURSE and ALDAY clinical trials are integral aspects of Daiichi Sankyo’s broader global clinical development program for mirogabalin, evaluating its use in pain syndromes including post-herpetic neuralgia, fibromyalgia and diabetic peripheral neuropathic pain.

Mirogabalin has been touted as a possible superior and safer competitor to Pfizer's (NYSE: PFE) blockbuster Lyrica (pregabalin), which generated sales of $4.17 billion last year.